Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
来自一项 II 期研究的恩沙替尼治疗克唑替尼耐药的 ALK 阳性非小细胞肺癌的最新总生存期和循环肿瘤 DNA 分析
期刊:Cancer Communications
影响因子:24.9
doi:10.1002/cac2.12524
Zheng, Jing; Wang, Tao; Yang, Yunpeng; Huang, Jie; Feng, Jifeng; Zhuang, Wu; Chen, Jianhua; Zhao, Jun; Zhong, Wei; Zhao, Yanqiu; Zhang, Yiping; Song, Yong; Hu, Yi; Yu, Zhuang; Gong, Youling; Chen, Yuan; Ye, Feng; Zhang, Shucai; Cao, Lejie; Fan, Yun; Wu, Gang; Guo, Yubiao; Zhou, Chengzhi; Ma, Kewei; Fang, Jian; Feng, Weineng; Liu, Yunpeng; Zheng, Zhendong; Li, Gaofeng; Wang, Huijie; Cang, Shundong; Wu, Ning; Song, Wei; Liu, Xiaoqing; Zhao, Shijun; Ding, Lieming; Selvaggi, Giovanni; Wang, Yang; Xiao, Shanshan; Wang, Qian; Shen, Zhilin; Zhou, Jianya; Zhou, Jianying; Zhang, Li
